ROCO
6496
Market cap36mUSD
Jul 09, Last price
25.35TWD
1D
1.81%
1Q
-4.88%
Jan 2017
-59.76%
IPO
-62.99%
Name
Excelsior Biopharma Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Excelsior Biopharma Inc., established in 1988 and headquartered in Taipei, Taiwan, functions as a pharmaceutical enterprise with a global market presence, encompassing Taiwan, China, and other international regions. The company offers a comprehensive range of healthcare solutions, including prescription and over-the-counter medications, medical devices, nutritional supplements, and various medical supplies. Excelsior addresses numerous therapeutic areas such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, otorhinolaryngology, and infectious disease management. Its product line also features specialized diagnostic kits under the Actim brand for identifying conditions like influenza virus, fecal occult blood, acute pancreatitis, and for assessing preterm or full-week delivery and early membrane rupture. Moreover, the company provides oral hygiene products, including toothpaste, mouthwash, and gels, under the Oral7 name. Beyond product sales, Excelsior is involved in the import and export of active pharmaceutical ingredients, as well as engaging in technological research, facilitating pharmaceutical technology transfer, and participating in collaborative development and improvement initiatives. The company adopted its current name, Excelsior Biopharma Inc., in June 2003, having previously been known as Excelsior Enterprise Co., Ltd.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||